

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

PROFIT WARNING

This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The board of directors (the “Board”) of The United Laboratories International Holdings Limited (the “Company”) wishes to inform the shareholders of the Company and the potential investors that, based on the unaudited consolidated management accounts of the Company and its subsidiaries (the “Group”) for the year ended 31 December 2025 prepared in accordance with Hong Kong Financial Reporting Standards, the Group is expected to record a profit of approximately RMB2,000,000,000 for the year ended 31 December 2025, while the profit for the year ended 31 December 2024 is approximately RMB2,658,000,000.

The decrease in profit is mainly due to decline in the market prices of Intermediate Products and Bulk Medicine during the year. The segment profit of Intermediate Products and Bulk Medicine decreased by approximately RMB1,600,000,000 and RMB400,000,000 respectively, as compared with 2024. The segment profit of Finished Products significantly increased by approximately RMB1,400,000,000 of which approximately RMB1,300,000,000 contributed from the license fee income from Novo Nordisk A/S during the year, partially compensated the decrease in segment profit of Intermediate Products and Bulk Medicine.

The information in this announcement is only based on the information currently available to the management of the Company. The results of the Group for the year ended 31 December 2025 have not yet been finalised nor reviewed by the audit committee and audited by the auditor. The final results of the Group for the year ended 31 December 2025 may be different to the information referred in this announcement.

Detailed annual results of the Group for the year ended 31 December 2025 will be published in the forthcoming 2025 annual results announcement and 2025 annual report of the Company.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 12 March 2026

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Ms. Zou Xian Hong, Ms. Zhu Su Yan and Mr. Fang Yu Ping as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.